Influenza Clinical Trial
Official title:
Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine
The study hypothesis is that two doses of cold-adapted, live monovalent A/17/mallard/Netherlands/00/95 (H7N3) influenza vaccine will be safe and immunogenic in healthy adults.
This is a phase I, double-blind, individually-randomized (3:1, vaccine:placebo), controlled
trial with two groups, LAIV H7N3 and matched placebo. Healthy male and female adults 18
through 49 years of age will be invited to participate. For feasibility reasons and in order
for an independent Safety Monitoring Committee (SMC) to review safety data in a small group
of subjects initially, the total cohort of 40 subjects will be enrolled in two sub-cohorts:
one cohort of 12 subjects, randomized at 3:1 (9 vaccine and 3 placebo), followed two weeks
later by a second cohort of 28 subjects randomized at 3:1 (21 vaccine and 7 placebo). After
all 12 volunteers of the first sub-cohort have been observed for the first isolation period
(Day 1 to Day 7), an interim safety review will be performed by the SMC. The SMC will review
all adverse events (AEs), including clinical laboratory evaluations (pre- and
post-vaccination) and shedding data, for all subjects and will advise if the volunteers of
the first sub-cohort may receive dose two of study vaccine or placebo and if the additional
28 volunteers of the second sub-cohort may be enrolled into the study. As for the first
sub-cohort, the SMC will also review all safety data for the second sub-cohort and for the
entire participant population of the trial. For each sub-cohort, the procedures and timelines
are here summarized.
On the day of first screening, about 7 days (between 4 and 14 days) prior to administration
of dose one of study vaccine or placebo, subjects will be screened for eligibility through
medical history review, physical examination, testing for serologic evidence of chronic viral
infection [human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus
(HCV), with proper pre- and post-test counseling], routine biochemical and hematological
blood tests and urinalysis by dipstick.
Subject screening for eligibility will continue and be completed on the second screening day
(S2). This second screening day will occur the same day as scheduled admission to the
isolation unit and administration of study vaccine or placebo (Day 0). Women will undergo
pregnancy tests using urine samples. All subjects will undergo an ear, nose and throat (ENT)
examination. Fully eligible subjects will be admitted to the isolation unit. At that time,
nasal swab, nasal wick, and blood specimens will be collected for virologic and immunological
testing prior to administration of study vaccine or placebo. Blood and urine specimens will
be again collected for routine biochemical and hematological blood tests and urinalysis by
dipstick; these results will serve to define baseline status for subject prior to receipt of
study vaccine or placebo but will not be used for screening purposes. Subjects will be
unaware of which allocation, LAIV H7N3 or matched placebo, is received; study vaccine and
placebo will be masked. Subjects will be carefully monitored for adverse reactions while in
the isolation unit.
All subjects will remain in the isolation unit for at least 7 days after receipt of study
vaccine or placebo. Nasal swabs will be collected daily while subjects are in isolation to
test for presence of influenza virus shed in the nasal passage. Any subject exhibiting
conjunctivitis will also have a conjunctival swab collected on the day of appearance of the
sign. Any subject exhibiting influenza A virus shedding, as determined by real-time reverse
transcriptase polymerase chain reaction (RT-PCR) positivity on a nasal swab specimen, in the
2 days prior to each planned discharge day after each dose (Days 6 or 7 or Days 34 or 35)
will be kept in the isolation until PCR-diagnosis results confirm that no influenza virus is
present in a tested clinical specimen for at least two consecutive days. Any subject still
exhibiting evidence of influenza virus shedding in a nasal swab on Days 6 or 7 or Days 34 or
35 post-administration with each dose might be placed on influenza antiviral (oseltamivir)
treatment at the standard dose for treatment of 75 milligrams (mg) twice a day for a course
of 5 days.
After discharge from the isolation unit, subjects will complete diary cards for AEs and use
of concomitant medications. Subjects will return to the isolation unit at four weeks (Day 28)
after administration of dose one of study vaccine or placebo. At that time, similar
procedures will be used for admittance to the isolation unit, for receipt of dose two of
study vaccine or placebo and for isolation and follow-up, with the additional procedure of
review of interim histories (and diary cards) since first discharge after dose one.
After second discharge from the isolation unit, subjects will again complete diary cards for
AEs and use of concomitant medications. Subjects will then return to the study center at four
weeks (Day 56) after administration of dose two of study vaccine or placebo for their final
study visit. Interim histories (and diary cards) will again be reviewed and final blood and
nasal wick specimens will be collected. Women will also undergo a final pregnancy screen.
Subjects will complete the study at this time.
For assessment of safety, subjects will be observed for two hours after each administration
of study vaccine or placebo. Twice daily (early morning and late afternoon) examination will
be also used to assess reactions for 7 days after each administration of study vaccine or
placebo. ENT examination will also occur once per day on Days 7, 28, 35 and 56. Subjects will
complete diary cards for unsolicited AEs from the day of each discharge until return to the
isolation unit for dose two (at Day 28) or until return to the study center for the final
study visit at four weeks post dose two (at Day 56). To assess safety, blood and urine
specimens will also be collected on days 7, 28 (prior to administration of dose two of study
vaccine or placebo), 35 and 56, for testing by routine biochemical and hematological blood
tests and by urinalysis by dipstick.
For the evaluation of mucosal immunoglobulin A (IgA) antibody, nasal wick specimens will be
collected on Day 0 (prior to administration of dose one of study vaccine or placebo), on Day
28 (prior to administration of dose two of study vaccine or placebo) and on Day 56. For the
evaluation of serum antibodies (by hemagglutination inhibition [HAI], microneutralization and
IgA and immunoglobulin G [IgG] EIA), serum specimens will be collected on Day 0 (prior to
administration of dose one of study vaccine or placebo), on Day 28 (prior to administration
of dose two of study vaccine or placebo) and on Day 56. To study virus infectivity (by
isolation in chicken embryos) and stability (by molecular sequencing of any isolated virus),
nasal swab specimens will be taken on Days 1, 2, 3, 5, 7, 29, and 31. To assess priming and
stimulation of cytotoxic T lymphocytes and other cytokine indicators, whole blood for
isolation of peripheral blood mononuclear cells (PBMCs) will be collected on Days 0 (prior to
administration of dose one of study vaccine or placebo), on Day 28 (prior to administration
of dose two of study vaccine or placebo) and on Day 56.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |